uniQure NV (QURE) Options

turnaround in the making

Here it comes
Still 11$ in cash and super science. Held back by blood leech Ex-Wallstreet CEO... BP wont care

Get in or don’t. It’s time
$QURE

Everyone forgot about this as they are much to busy chasing the next ultra risky 10% flip.
SOOO undervalued. Suppressed by bored traders and gamblers leaving.
The data will speak again and people will realize this is worth 2-4bn.

Buying for swing. Tier 1

Agree until more news is released.

Got in at 5.85, I’ll be out tomorrow, this one is done.

WTH? New LOD every time I check.

Nope

Turd city…

Even less volume today than last Friday.

Agree. Odd that it trades in the 8’s

I became an investor the second i saw the results but i also traded around my position. Ergo I am riding a free ticket now.
Company has 11$ per share in cash and the science is probably worth 2-4bn $.

Bull or bear?

Looked like crapola today

Flagg forming

institutions use liquidity = take a seat and watch the scenario unfold.

We’ll see. 80% drop in volume today.

UniQure Interesting move here solid pipeline added a few calls for early July for fun.
Keep an eye o Ice Cure killing cancer by cryoblation ICCM one of the most undervalued stocks.
$QURE

Great chart. Shooting for a rip beteen $12.41-$16.75.

traders are too busy trying to make $ in silly names. Every few months there is a play like this.... that doesnt require much thinking-- only spotting it and letting the big guys do the lifting.

Listen to Victor Sung on the recent call. You dont need to be in the know to hear he hasnt seen anything similar

https://edge.media-server.com/mmc/p/m4opdukf

QURE under $5

$QURE $5.14 buy it up

QURE

$26.36 +3.36 (+14.61%)
As of Nov-23-20224:00:00 PM ET

https://stockcharts.com/h-sc/ui?s=QURE

FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
BENZINGA 8:12 AM ET Nov-23-2022

UniQure N.V.'s (NASDAQ:QURE) partner CSL Limited (OTC:CSLLY) has received FDA approval for Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B.
CSL licensed the exclusive global rights to Hemgenix from uniQure in May 2021.
UniQure has received about $500 million so far from CSL and will also be eligible to get up to an additional $1.5 billion in commercial milestone payments and royalties.
Cowen analyst Joseph Thome said that Hemgenix's price of $3.5 million is higher than the brokerage's estimated $1.9 million, but its consultants have been optimistic about the therapy's uptake, Reuters reported.
Results from the pivotal HOPE-B trial support the FDA approval, the largest gene therapy trial in hemophilia B.
Results from the study demonstrated that Hemgenix allowed patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post-infusion.
Seven to 18 months post-infusion, the mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by 54% compared to the six-month lead-in period on factor IX prophylactic replacement therapy (4.1 to 1.9).
In addition, 94% of patients treated with Hemgenix discontinued prophylaxis and remained free of previous continuous routine prophylaxis therapy.
The FDA has already cleared two gene therapies, Zynteglo and Skysona, from Bluebird bio Inc (NASDAQ: BLUE) in August and September, respectively.

Whoops!

Insiders selling big time while biopharmcatalyst site tries to pump - noit a good sign

Profit taking time .. Good time to short this .. I want to be in for a short

QURE $9.15 high today, nice.

This thing is pretty volatile lately.

QURE Looked great hitting $9.00 today

QURE General Information

http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=QURE.O

Uniqure NV (QURE) Money Flow Index Nearing Key Level

http://tuckermantimes.com/uniqure-nv-qure-money-flow-index-nearing-key-level/247578/

Erratic Trading Showing Unusual Volume in Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) and uniQure N.V. (NASDAQ:QURE)

https://www.concordregister.com/erratic-trading-showing-unusual-volume-in-shares-of-concert-pharmaceuticals-inc-nasdaqcnce-and-uniqure-n-v-nasdaqqure/

uniQure N.V. NASDAQ:QURE Sees High Volatility in Session

https://aikenadvocate.com/uniqure-n-v-nasdaqqure-sees-high-volatility-in-session/290264/

uniQure N.V. (QURE) PT Set at $13.00 by Chardan Capital

https://weekherald.com/2017/07/24/uniqure-n-v-qure-pt-set-at-13-00-by-chardan-capital.html

This dog has always been a turd. Why did it run last couple days? Already see signs of rollover on today's intraday imo. $QURE

buying here

Lost all patience in this pos

Patient is a virtue.
If you know what you are doing it pays off.

That's why it's down another 3%

Trust me they are. They just don't want you to think that way.

The market does not seem to be overly impressed.

Great news out

Great newsGo QURE

uniQure N.V. (NASDAQ:QURE) announced the completion of a company-wide strateghttp://www.benchmarkmonitor.com/2016/11/17/uniqure-n-v-nasdaqqure-announced-the-completion-of-a-company-wide-strategic-review/ic review


uniQure N.V. (NASDAQ:QURE), announced the completion of a company-wide strategic review aimed at refocusing its pipeline, consolidating its manufacturing and enhancing overall execution to drive shareholder value. As a result of this initiative, the Company will prioritize programs in hemophilia B, Huntington’s disease and those associated with its landmark collaboration with Bristol-Myers Squib (BMS) in cardiovascular disease.

uniQure N.V. (NASDAQ:QURE), a Healthcare sector firm, traded 495604 shares in last trading session with closing price of $7.04 per share. Company gross margin stands at 94.90% whereas its return on investment (ROI) is -49.30%. Stock value has moved between $6.64 – 22.71 in last one year. Analyst’s mean target price for uniQure N.V. (NASDAQ:QURE) is $30.10 while analysts mean recommendation is 1.60. QURE EPS growth this year is -49.60%.

I see over 100 % upside from here. Go QURE

Not sure but panzers got blasted. Data in December so will average down here and stay put

WTF happened here today?

Adding all under 9s

QURE data will show in PPS hang on tight